FDA Determines Regulatory Review Period for BAROSTIM NEO Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for BAROSTIM NEO, a medical device patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).